Occurrence of Existing BCR-ABL Baseline Mutations and Associated Haplotype (NmR) Among CML Patients with Diverse IM Response: A Hospital-based Study from North-East India-Reference-Cited by-同舟云学术

Occurrence of Existing BCR-ABL Baseline Mutations and Associated Haplotype (NmR) Among CML Patients with Diverse IM Response: A Hospital-based Study from North-East India

Published:2024-02-16 Issue: Volume: Page:
ISSN:0006-2928
Container-title:Biochemical Genetics
language:en
Short-container-title:Biochem Genet

Author:

Hazarika Gautam,Kalita Manash Jyoti,Das Partha Pratim,Kalita Simanta,Dutta Kalpajit,Lahkar Lipika,Rajkonwar Anjanjyoti,Idris Mohammed Ghaznavi,Khamo Vinotsale,Kusre Giriraj,Medhi Subhash

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10528-024-10676-x.pdf

Reference27 articles.

1. Al-Ouqaili MTS, Majeed YH, Al-Ani SK (2020) SEN virus genotype H distribution in β-thalassemic patients and in healthy donors in Iraq: molecular and physiological study. PLoS Negl Trop Dis 14(6):e0007880. https://doi.org/10.1371/journal.pntd.0007880

2. Annamaneni S, Kagita S, Gorre M, Digumarti RR, Satti V, Battini MR (2014) Methylation status of CEBPA gene promoter in chronic myeloid leukemia. Hematology 19(1):42–44. https://doi.org/10.1179/1607845413Y.0000000081

3. Bradeen HA, Eide CA, O’Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations. Blood 108(7):2332–2338. https://doi.org/10.1182/blood-2006-02-004580

4. Corbin AS, Rosée PL, Stoffregen EP, Druker BJ, Deininger MW (2003) Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101(11):4611–4614. https://doi.org/10.1182/blood-2002-12-3659

5. de Lavallade H, Kizilors A (2016) The importance of mutational analysis in chronic myeloid leukaemia for treatment choice. EMJ Oncol. https://doi.org/10.33590/emjoncol/10311536